ClinicaliQ Trial Snapshot
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment — Active Not Recruiting • Phase III • NCT04576156.
- Imetelstat improves survival compared to standard treatment in patients with advanced myelofibrosis who haven't responded to JAK inhibitors.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment. Conditions: Myelofibrosis Interventions: Imetelstat, Best Available Therapy (BAT) Lead Sponsor: Geron Corporation Planned Enrollment: 327 participants